Dapagliflozin Tablet, Film Coated
Product Images NDC 50090-7057

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 50090-7057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
FDA Label Image

Figure_1 (Farxiga Fig1)

Figure_1 (Farxiga Fig1)
Not available.*
FDA Label Image

Figure_10a (Figure 10a)

Figure_10a (Figure 10a)
FDA Label Image

Figure_10b (Figure 10b)

Figure_10b (Figure 10b)
FDA Label Image

Figure_11 (Figure 11 01)

Figure_11 (Figure 11 01)
FDA Label Image

Figure_8b (Figure 8b)

Figure_8b (Figure 8b)
FDA Label Image

Figure-9b (Figure 9b 01)

Figure-9b (Figure 9b 01)
FDA Label Image

Figure_2 (Image 01)

Figure_2 (Image 01)
FDA Label Image

Figure_3 (Image 02)

Figure_3 (Image 02)
FDA Label Image

Figure_6 (Image 03)

Figure_6 (Image 03)
FDA Label Image

Figure_7a (Image 04)

Figure_7a (Image 04)
The given text provides information about a study comparing the effects of Dapagliflozin to a placebo in patients. The text includes the percentage of patients with an event in each group, the hazard ratio (HR) and its confidence interval (95% CI), as well as the p-value comparing Dapagliflozin to the placebo. It also includes the number of patients at risk over different time intervals. Based on this information, it appears that Dapagliflozin has a significant effect in reducing the occurrence of the event compared to the placebo.*
FDA Label Image

Figure-7b (Image 05)

Figure-7b (Image 05)
Not available.*
FDA Label Image

Figure-8a (Image 06)

Figure-8a (Image 06)
The text contains data comparing the effectiveness of Dapagliflozin versus Placebo in patients. The percentage of patients with a certain condition is mentioned, along with the HR (Hazard Ratio) and P-value. There is also a timeline showing the number of months from randomization and the number of patients at risk for both Dapagliflozin and Placebo.*
FDA Label Image

Figure-9a (Image 07)

Figure-9a (Image 07)
FDA Label Image

Label Image (Lbl500907057)

Label Image (Lbl500907057)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.